Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma

por Ailawadhi, Sikander, Panjabi, Sumeet, Campioni, Marco, Majer, Istvan, Jakubowiak, Andrzej
Publicado 2018

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

por Delea, Thomas E., Zhang, Xinke, Amdahl, Jordan, Boyko, Diana, Dirnberger, Franziska, Campioni, Marco, Cong, Ze
Publicado 2019

Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting

por Bouwmeester, Walter, Briggs, Andrew, van Hout, Ben, Hájek, Roman, Gonzalez-McQuire, Sebastian, Campioni, Marco, DeCosta, Lucy, Brozova, Lucie
Publicado 2019

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review

por Hájek, Roman, Gonzalez-McQuire, Sebastian, Szabo, Zsolt, Delforge, Michel, DeCosta, Lucy, Raab, Marc S, Bouwmeester, Walter, Campioni, Marco, Briggs, Andrew
Publicado 2020

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making

por Gonzalez-McQuire, Sebastian, Dimopoulos, Meletios-Athanassios, Weisel, Katja, Bouwmeester, Walter, Hájek, Roman, Campioni, Marco, Bennison, Craig, Xu, Weiwei, Pantiri, Krystallia, Hensen, Marja, Terpos, Evangelos, Knop, Stefan
Publicado 2019